Purpose: To investigate how patients with neovascular age-related macular degeneration treated with ranibizumab or bevacizumab respond to treatment in daily clinical practice.
N eovascular age-related macular degeneration (nAMD) is one of the leading causes of visual impairment in the elderly population in the Western World. 1 The standard treatment for patients with nAMD is anti-vascular endothelial growth factor intravitreal injections. At present, there are two different drugs approved to treat nAMD: ranibizumab (Lucentis; Genentech Inc, South San Francisco, CA) and aflibercept (Eylea; Bayer Pharma AG, Berlin, Germany). In clinical trials, both drugs have demonstrated positive effects in maintaining and, in some cases, improving patients' visual acuity after 1 year and 2 years of treatment. [2] [3] [4] In clinical practice, the off-label drug bevacizumab (Avastin; Genentech Inc) is also widely used to treat patients with nAMD. Bevacizumab has significantly lower cost per dose compared with that of aflibercept and ranibizumab. 5 Two clinical trials compared ranibizumab and bevacizumab using different treatment frequencies showing that bevacizumab was not inferior to ranibizumab if applied with the same frequency. [6] [7] [8] Several observational studies followed the first clinical trials and were undertaken in settings similar to daily clinical practice. [9] [10] [11] [12] These studies did not show as large beneficial effects as the mentioned clinical trials. Therefore, the size of the benefit experienced by the patients and the optimal treatment setting in daily clinical practice are still not completely established.
The aim of this study was to add further knowledge about how patients with nAMD are treated in daily clinical practice and the results of the treatment. Information about the treatment received by 3,912 patients with nAMD in Sweden during the period 2011 to 2014 is presented. The data are obtained from the Swedish Macula Register (SMR). This register collects information about most patients treated in Sweden for nAMD from the first visit (diagnostic visit) until the patient finishes receiving treatment. This study focused on patients treated with either ranibizumab or bevacizumab who had their diagnostic visit in the period 2011 to 2012. The records of those patients were followed until 2014, thus obtaining a 2-year follow-up period. Data for patients' characteristics at the first visit, changes in visual acuity at 1 year and 2 years after starting the treatment, number of injections received over time, and the reason for terminating the treatment if applicable are presented. The risk of having poor vision (visual acuity under 60 Early Treatment Diabetes Retinopathy Study [ETDRS] letters or approximately 20/60 Snellen) for the treated eye after 1 year and 2 years of treatment is estimated. The number of patients who need visual rehabilitation after 1 year and 2 years is also calculated. In the text, visual acuity less or equal to 60 ETDRS letters or approximately 20/60 Snellen will be referred to as visual acuity #60 letters.
Methods

Study Design and Cohort
This project was approved by the Lund University Ethical Board in September 2015 (Dnr 2015/679). The data were obtained from the SMR, after approval from its steering committee. The SMR started collecting information about treatment of intravitreal injections in 2008. The register is financed by the Swedish Association of Local Authorities and Regions and collects data from patients treated for nAMD from several medical centers across Sweden for both quality improvement and research purposes. The participating centers are privately or publicly owned. The patients attending those centers come from all socioeconomic statuses since treatment for nAMD is fully reimbursed within the public health care system for Swedish residents. When attending the clinic, the patients are informed about the register, and only data from those who agree to be part of the register are collected. Some of the variables recorded by the register are the patient's unique personal identity number, visit dates, received treatment, visual acuity for both the treated and the fellow eye, retina status at diagnosis, and reason to end of treatment. It is worth noticing that the SMR does not require registration of the best-corrected visual acuity. However, our experience indicates that most nurses and doctors do register best-corrected visual acuity. The coverage during the period 2011 to 2014 is approximately 80%, which means that approximately 80% of all patients treated in Sweden for nAMD have records in SMR. The data obtained from SMR were further linked to the Swedish People and Address Register (SPAR) managed by the Swedish Tax Office, to obtain information about the death date if applicable.
Data were collected for all patients for whom their first visit (visit at which the patient was diagnosed with nAMD) took place in the period of January 1, 2011, until October 31, 2012 (Figure 1 ). During this period, most patients were treated with bevacizumab or ranibizumab. The sample included all visit records for those patients until December 31, 2014, to get a complete 2-year follow-up period.
We excluded the data of the following cases: eyes that were treated previously for nAMD and those who switched treatment drug, for example received first bevacizumab and then ranibizumab. Eyes with incomplete visual acuity assessment at the first visit and patients who were not found in the Swedish People and Address Register were also excluded from the analysis. Finally, our data set included 3,365 and 547 eyes treated only with ranibizumab and bevacizumab, respectively.
Outcome Measurements
The visual acuity at the first visit (baseline) and after 1 year and 2 years for the treated eye, the number of injections received by the patient over time, and the reason for discontinuing the treatment if applicable are reported. The number of patients with visual acuity $60 letters for both eyes at the beginning of the treatment, and after 1 year and 2 years is also listed. The first year visit is defined as the latest visit in the period 10 months to 14 months after the first visit. The second year visit is defined as the latest visit in the period 22 months to 26 months from the first visit. We mostly discuss the results obtained including only patients who continued the treatment and have a complete follow-up (similar to per protocol population). For comparison purposes, the same analyses are presented for all patients in the cohort, including those who do not have a 1-year and/or 2-year visit (similar to the intention-to-treat population).
Some eyes did not have ETDRS values but had Snellen values and those were converted to ETDRS according to Gregori et al. 13 In total, approximately 15% of the ETDRS values were converted from Snellen values.
Statistical Analyses
To describe the study population, the median was used as a tendency parameter, because the distributions were skewed. The standard deviation was reported as a measure of the spread of the distributions. The risk of attaining visual acuity #60 letters for the treated eye at 1 year and 2 years after treatment start was calculated using a generalized linear model. Briefly, it is a technique used to calculate the probability of an outcome, in this case attaining a visual acuity #60 letters, taking into account simultaneously several risk factors, such as age and amount of injections. In this study, we analyzed the total number of injection received during the first year and the first 2 years. To minimize the risk of introducing immortal bias in the results, 14 we avoided analyzing the number of injections received only during the second year. Immortal bias could be caused by not including those patients who did not respond to treatment and who did not receive undergo treatment during the second year. In this case, there is a risk that overrated results are obtained because patients with deteriorated visual acuity are not included in the analysis for the second year of treatment. Some patients were treated on both eyes (approximately 5% bilateral cases), and therefore the intragroup correlation was taken into account in the models.
The most frequently used link functions are the logitlink, the probit-link, and the log-link. The logit and probit functions behave well numerically; however, the interpretation of the results is not straightforward. However, the log-link has the advantage that it allows interpreting the model coefficients directly in terms of relative risk. When the log-link is used, the fitted probabilities may exceed 1, although this problem rarely occurs in practice. 15 To facilitate interpretation of the results, we applied the log-link function in the model. For all analyses, the statistical significant level was set at 5% and the P values are two-sided.
To enable finding a suitable statistical model, the data were divided into patients who had a visual acuity fewer than or equal to 60 letters at the first visit and patients who had a visual acuity more than 60 letters at the first visit. The reason to fit different models was that the effect of receiving more treatment on the risk of attaining a visual acuity #60 letters was different for these groups. One model was fitted to calculate the risk of having a visual acuity #60 letters after 1 year of treatment and another for the 2 years of treatment.
The goal of the statistical analysis was to find models that fitted the data adequately and had clear clinical interpretation. For all cases, the final model was selected after performing several steps. First, we included as explanatory variables all the registered variables that we considered could affect the risk of having a visual acuity #60 letters at the end of the treatment year. The first model included a binary variable to indicate whether the patient was older than 79 years when starting the treatment, an indicator variable to describe whether the patient received more than the median number of injections during the treatment year (first year and up to 2 years), a categorical variable indicating the retina status at the first visit, an indicator variable for treatment drug, and a categorical variable indicating the duration of the symptoms before starting treatment. The variables that were not statistically significant were removed one by one, and the model was refitted with the remaining variables. The final model only contained those variables found to be statistically significant. The remaining variables in the models were the indicator variables, age (younger/older than 79 years) and whether the patient received more injections that the median for the corresponding treatment year. The models were validated using a residual analysis.
Results
Study Population and Baseline Characteristics
There were 3,365 and 547 eyes treated only with ranibizumab and bevacizumab, respectively. The treatment received by the patients was decided by the physician and was influenced by several factors such as patients' characteristics, routines in the clinic, availability of the treatment drug, costs, etc. The main characteristics of the patients were similar for both treatment arms (Table 1 ). The median age of the patients was approximately 79 years, and above 60% of the patients were women. Approximately 40% of the patients experienced nAMD symptoms for less than 2 months before their first visit. The most frequent retina status at the first visit was 100% occult lesions (approximately 35% of the patients) followed by dominantly classic lesions (approximately 25% of the patients). The visual acuity at the first visit was also similar for both treatment groups ( Table 2 ). The median number of letters was approximately 58 with a large spread of values (standard deviation 15 letters). Approximately 57% of the patients saw 60 letters or fewer at their first visit.
One Year Follow-up
The results obtained after 1-year follow-up treatment are listed in Table 2 . Also in this case, the values were similar for both treatment groups. After 1-year, the median total number of injections for the patients with complete 1-year follow-up data was five with a large standard deviation, which means that some patients received more than five injections whereas others received fewer. The median visual acuity was approximately 65 letters (standard deviation approximately 17 letters) for both treatment groups. The median difference in visual acuity between the 1-year visit and the baseline visit was +3 letters. However, the variation between the patients was substantial (standard deviation approximately 15 letters). After 1 year of treatment, approximately 40% of the eyes had a visual acuity #60 letters. Twenty-seven percent of the treated patients improved their visual acuity more than 10 letters, whereas approximately 15% of the eyes improved their visual acuity more than 15 letters. Eighteen percent of the treated patients lost more than 10 letters, whereas approximately 12% of the eyes lost more than 15 letters.
The reasons why patients were lost to follow-up are listed in Table 3 . There were 1,041 (31%) and 131 (24%) eyes without a complete 1-year follow-up for the ranibizumab and bevacizumab groups, respectively. The most frequent reasons were termination due to low visual acuity, paused without specific reason, and missing values (Table 3) . The first visit is defined as the visit in which the patient was diagnosed with nAMD. Patients with a complete 1-year follow-up have a visit in the period 10 months to 14 months from the first visit. Patients with a complete 2-year follow-up have a visit in the period 22 months to 26 months.
PCV, polypoidal choroidal vasculopathy; RAP, retinal angiomatous proliferation. 
Two-Year Follow-up
The results obtained after 2 years of treatment are listed in Table 2 . As for the 1-year follow-up outcomes, the results were similar in both treatment groups. The median total number of injections received during 2 years (first year plus second year) for the patients with complete 2-year follow-up was seven (standard deviation 3.2 injections) and eight (standard deviation 4.5 injections) for the ranibizumab group and bevacizumab group, respectively. The median visual acuity was approximately 65 letters (standard deviation approximately 17 letters) for both treatment groups. The median difference in visual acuity between the 2-year visit and the baseline visit was +2 and +1 for the ranibizumab group and bevacizumab group, respectively. However, the variation between the patients was large (standard deviation approximately 16 letters). After 2 years of treatment, approximately 40% of the eyes had a visual acuity #60 letters. For the patients treated with ranibizumab, 26% improved their visual acuity more than 10 letters, whereas approximately 15% of the eyes improved their visual acuity more than 15 letters. The first visit is defined as the visit in which the patient was diagnosed with nAMD. For all patients, the first year visit is defined as the latest visit to 14 months from the first visit. The second year visit is defined as the latest visit to 26 months from the first visit. Patients who have a visit in the period 10 months to 14 months from the first visit are considered to have a complete 1-year follow-up. Patients who have a visit in the period 22 months to 26 months from the first visit are considered to have a complete 2-year follow-up. In both cases, the latest visit is considered the follow-up visit.
VA, visual acuity. Twenty percent of the treated patients lost more than 10 letters, whereas approximately 13% of the eyes lost more than 15 letters. For those treated with bevacizumab, approximately 24% improved their visual acuity more than 10 letters, whereas approximately 14% of the eyes improved their visual acuity more than 15 letters. Twenty-two percent of the treated patients lost more than 10 letters, whereas approximately 16% of the eyes lost more than 15 letters. There were 1,882 (56%) and 242 (44%) eyes without a complete 2-year follow-up for the ranibizumab group and bevacizumab group, respectively. The most frequent reasons for lost to follow-up at 2 years are similar to those for 1 year follow-up: termination due to low visual acuity, paused without specific reason, and missing values (Table 3) .
Risk for Having a Visual Acuity #60 Letters (approximately 20/60 Snellen) After 1 Year and 2 Years of Treatment
To estimate the risk of low visual acuity, two statistical models were calculated: one for patients with low visual acuity at baseline and another one for patients with high visual acuity at baseline. Furthermore, one model calculated the risk of having a visual acuity #60 letters after 1 year of treatment and another model calculated the risk after 2 years of treatment. In total, four statistical models were calculated. The results are listed in Table 4 .
In the case of patients with visual acuity #60 letters, the results were similar after 1 year and 2 years of treatment. The crude risk (risk without taking into account any explanatory factors) for maintaining a low visual acuity after 1 year of treatment is 0.64 (95% confidence interval [CI] 0.619-0.670) with P , 0.0001 (Table 4) . This indicates that after 1 year of treatment, approximately 64% of the patients would still have a low visual acuity. After 2 years of treatment, the crude risk is 0.61 (95% CI 0.582-0.649) with P , 0.0001, which means that approximately 61% of the patients who complete 2 years of treatment would have a low visual acuity.
To estimate how the risk of having low visual acuity is affected by treatment drug, age, and the total number of injections received, a model was calculated including those variables as explanatory variables. There was no statistical significant difference in the risk of having a visual acuity #60 letters for patients who treated with bevacizumab compared with those treated with ranibizumab (risk for 1 year: 1.0 [95% CI 0.900-1.113]; P = 0.983, risk for 2 years: 1.08 [95% CI 0.941-1.236]; P = 0.280). In other words, our results indicate that for patients with similar age (older/younger than 79 years) and number of injections receiving bevacizumab did not affect the risk compared with those who received ranibizumab.
To obtain more efficient estimates for the effect of age and number of injections, we removed the variable treatment from the statistical model and calculated a new model ( Similar models were fitted using data for patients who had a visual acuity .60 letters at the first visit ( Table 4 ). The crude risk was 0.20 (95% CI 0.178-0.221) with P ,0.0001 and 0.25 (95% CI 0.228-0.283) with P ,0.0001, for patients with a complete 1-year and 2-year follow-up, respectively. This indicates that approximately 20% and 25% of patients would have a low visual acuity after 1 year and 2 years of treatment, respectively.
Also in this case, we do not observe a statistically significant difference in risk for patients treated with bevacizumab compared with those treated with ranibizumab (risk for 1 year: 0.77 [95% CI 0.554-1.079]; P = 0.131, risk for 2 years: 1.00 [95% CI 0.750-1.322]; P = 0.977).
An increase in age has a negative effect on visual acuity. After 1 year and 2 years of treatment, patients older than 79 years would have approximately 49% (1.49 [1.198-1.857 ]; P ,0.0001) and 38% (1.38 [1.108-1.717]; P = 0.004) higher risk of low visual acuity compared with younger patients, respectively (Table 4 ). For patients with higher visual acuity at the first visit, receiving more than five injections does affect the risk of attaining a low visual acuity after 1 year of treatment (1.45 [95% CI 1.150-1.820]; P = 0.002). Patients who received more than five injections during the first year had 45% statistically significant increased risk of attaining low visual acuity compared with those who received fewer injections. After 2 years of treatment, patients who received fewer than seven injections during 2 years do not have statistically significant higher risk compared with those receiving less treatment (1.10 [95% CI 0.882-1.364]; P = 0.406).
Estimated Number of Patients Who Need Vision Rehabilitation After 1 Year and 2 Years of Treatment
In Sweden, low vision centers provide visual rehabilitation in case of visual acuity of the bestseeing eye being less or equal than 60 letters ETDRS or approximately 20/60 Snellen, significantly restricted visual fields or presence of homonymous hemianopia. Patients fulfilling these conditions are entitled a referral to a vision rehabilitation center. The number of patients with visual acuity fewer than 60 letters on both eyes is calculated. After 1 year of treatment, 750 (22%) patients treated with ranibizumab were entitled to vision rehabilitation. For those treated with bevacizumab, 129 (24%) needed vision rehabilitation. At the end of the 2-year period, there were 1,197 (36%) patients treated with ranibizumab and 218 (40%) treated with bevacizumab who needed vision rehabilitation.
Discussion
In this article, information about the treatment given to patients diagnosed with nAMD during 2011 to 2012 The response variable is a binary variable that indicates whether the visual acuity (VA) for the treated eye is fewer than 60 letters (approximately 20/60 Snellen) at the first/second-year follow-up. Two binary variables are included in the model as covariates: one indicates whether the patient was older than 79 years and the other indicates whether the patient received more than the number of median injection during the first/second year. The results from the crude model (without covariates) are also presented. The first visit is defined as the visit in which the patient was diagnosed with nAMD. For all patients, the first year visit is defined as the latest visit to 14 months from the first visit. The second year visit is defined as the latest visit to 26 months from the first visit. Patients who have a visit in the period 10 months to 14 months from the first visit are considered to have a complete 1-year follow-up. Patients who have a visit in the period 22 months to 26 months from the first visit are considered to have a complete 2-year follow-up. In both cases, the latest visit is considered the follow-up visit.
with a 2-year follow-up period is presented using realworld data from the SMR. The change in visual acuity at 1 year had a median of +3 letters and a standard deviation of 15 letters for patients treated with ranibizumab or bevacizumab. At 2 years, the change in visual acuity from the first visit had a median of +2 (ranibizumab) and +1 (bevacizumab) letters and standard deviation of 17 letters. For both time points, there was a large spread indicating that some patients improved their visual acuity whereas others attained a lower visual acuity value. As expected, the effect of age is negative for the development of visual acuity. It could be due to biological reasons, or also due to the difficulties in attending the eye clinic due to other diseases that may be present at higher age. After 1 year and 2 years of treatment, approximately 20% and 40% of the patients required vision rehabilitation, respectively.
The efficacy of ranibizumab for the treatment of nAMD was shown in several clinical trials. 2, 3, 9, 12, 16, 17 The MARINA clinical trial compared ranibizumab against placebo in 716 patients. 3 The authors observed that visual acuity improved by 15 or more letters in approximately 25% to 34% of the study population, and the mean increased in visual acuity was approximately 6.5 to 7 letters after 1-year and 2-year follow-up. The ANCHOR study compared ranibizumab against verteporfin photodynamic therapy including 423 patients with nAMD 2 with 1-year and 2-year follow-up. Approximately 34% to 41% of the patients treated with ranibizumab had gained more than 15 letters and, on average, visual acuity was improved from baseline by 8.1 to 10.7 letters. Similar results were obtained in the FOCUS trial with 162 patients. 16 Some clinical trials that compared bevacizumab with ranibizumab showed that the two drugs have similar efficacy if applied in a similar way. [6] [7] [8] The CATT and IVAN trials compared the effect of bevacizumab with the effect of ranibizumab at 1-year and 2-year followup. 6, 7 The CATT trial found that patients' visual acuity improved on average 6.8 and 8.5 letters with ranibizumab administered monthly and as needed, respectively. 7 The visual acuity of patients receiving bevacizumab improved on average 8 and 5.9 letters for those following monthly and as-needed regime, respectively. 7 The IVAN trial reported that after 2-year follow-up, the visual acuity of patients receiving ranibizumab improved 4.9 letters on average, whereas the visual acuity of patients receiving bevacizumab improved 4.1 letters on average. 6 Our results regarding the improvement in visual acuity are lower compared with those reported in clinical trials (Figure 2 ). Other observational studies also found lower visual acuity improvement. [10] [11] [12] These differences could be due to different treatment programs and differences between the study populations. The patients participating in the mentioned clinical trials were specially recruited and received closer follow-up and a larger amount of injections compared with the patients in this study. In general, patients enrolled in clinical trials are carefully selected and follow a strict treatment program, whereas our study included an unselected population treated in standard clinical practice. In the CATT and IVAN studies, the authors found that patients who received more injections showed slightly better functional outcomes. 6, 7 These findings suggest that increasing the treatment frequency improves the visual acuity. The patients in this study received on average fewer injections compared with the mentioned clinical trials, which probably had an effect on the development of the visual acuity. Our results are consistent with the finding observed in the clinical trials comparing the effect of ranibizumab and bevacizumab because we are unable to observe any clinical or statistically significant differences between the patients who received ranibizumab and those who received bevacizumab.
AURA was an observational multicountry study including 2,227 patients treated with ranibizumab in standard clinical practice. 11 The authors found that the number of injections given in clinical practice is less than in clinical trials (mean injections at 1 year = 5 and at 2 years = 2.2) and that the mean change in visual acuity was +2.4 and +0.6 letters at 1 year and 2 years, respectively. Holz et al 11 also found that more frequent visits and injections were associated with greater improvement in visual acuity. Our results are similar to those reported in AURA regarding visual acuity and the number of injections. However, we do not observe a protective effect of the number of injections in visual acuity. Injections less than once a month result in a small decrease in mean visual acuity, shown in CATT and IVAN trials. Fewer injections Year 1 and especially Year 2 in our study could have an effect on the visual acuity results and explain the inability to maintain visual acuity during Year 2. These differences could also be due to differences in the patient population and in the clinical routines in Sweden compared with the countries that participated in AURA.
It is worth noticing that because our data are observational, it is not possible from our results to imply causal association between the number of received injections and the development of the visual acuity. Our results indicate that for patients with fewer than 60 letters visual acuity at baseline, receiving more than 5 injections during the first year or more than 7 (ranibizumab) or 8 (bevacizumab) injections during the first 2 years of treatment neither increase nor decrease statistically the risk of remaining with low visual acuity. In other words, our results do not show that patients with low visual acuity at baseline who received more injections performed better than patients who received less injections. For patients with visual acuity .60 letters at baseline, our results indicate that the patients who received more than 5 injections during the first year had between 15% and 82% larger risk of attaining a visual acuity #60 letters compared with patients who received less than 5 injections. A plausible explanation could be that because most doctors would expect patients to maintain their visual acuity with treatment, those receiving more treatment were those who became worse during the treatment year, and therefore they had an increased risk of attaining a visual acuity under 60 at 1-year follow-up. Our data show neither a protective nor a negative effect of increasing the number of injections to more than 7/8 injections during the first 2 years of treatment. However, because several parameters that may affect the development of the disease, such as severity, are not included in our model, it is not possible to separate this effect from the effect given by treatment frequency in the development of the visual acuity. Therefore, our results are inconclusive regarding the effect of the injections, and further research on the optimal number of injections for different group of patients in standard clinical practice is needed.
The analyses presented here have several limitations. Our results are based on register data, which is neither totally complete nor correct. The SMR estimates errors and missing values to be approximately 5%, 1%, and 13% for ETDRS, number of injections, and Snellen, respectively. Approximately 15% of the ETDRS values were converted from Snellen, which could introduce errors in particularly at low visual acuity. Not all the patients had a complete follow-up at 1 year and 2 years. A total of 2,740 (70%) eyes had a complete 1-year follow-up visit and 1,788 (45%) eyes had a complete 2-year follow-up visit. Some patients died before the 1-year and 2-year periods were completed (4% at 1 year and 9% at 2 years). We addressed these difficulties by performing the analysis in two different data sets, one with the complete data and the other with the available data. Because the results are similar for both data sets, we believe that the bias effects due to missing data and misclassifications probably are negligible. To obtain a model that fitted the data adequately, only the variables recorded in the register were used. The visual acuity could be affected by other variables, such as severity of the disease, activity in the retina, etc, that are not collected by the SMR and could be important for the estimation of the risk of having a visual acuity #60 letters. Additionally, because the analyses are performed using a large database, some parameters might be statistically significant just because of the large amount of included patients. To determine which parameters are clinically significant, we present the CIs together with the P values to clearly state the range of plausible values for the calculated parameters.
One of the main advantages of our study is that a very large number of eyes are included in the analysis. Furthermore, our results are obtained using an unselected population. The risk estimates presented in this study are obtained using most of the patients who received treatment for nAMD in Sweden. We also obtained similar results when using the complete data set (similar to the intention-to-treat population) or only those patients who had a complete follow-up (similar to per protocol population).
Overall, we observed that the treatment with antivascular endothelial growth factor drugs helps patients to maintain their visual acuity level, which is an important progress in the treatment of nAMD. The treatment outcome largely depends on the visual acuity of the patient at the first visit. For those patients with visual acuity .60 letters, the risk of having a visual acuity #60 letters after 1 year or 2 years of treatment is approximately 20%. However, for patients with low visual acuity at diagnosis (#60 letters), the probability of attaining a visual acuity #60 letters is approximately 60% after 1 year or 2 years of treatment. Our study also indicates that the risk of having a visual acuity #60 letters is independent of the treatment drug, meaning that in our population, patients treated with bevacizumab have similar risk compared with those treated with ranibizumab. As expected, the risk of low visual acuity depends on the age of the patient, older patients have a higher risk compared with younger patients.
The effect of the number of injections on visual acuity in standard clinical practice is not well established. Clinical trials suggest that patients receiving monthly injections had slightly better outcomes compared with patients treated as needed. 6, 7 Our results may indicate that the effect of the number of injections in visual acuity could be related to the visual acuity level of the patients when they start the treatment. For patients with visual acuity #60 letters at baseline, the risk of low visual acuity after 1 year and 2 years of treatment is similar for all patients regarding the number of received injections. However, for patients with visual acuity .60 letters at baseline, there seems to be a negative association between the number of injections and the risk of attaining a lower visual acuity. It is observed that patients who received more injections have developed worse visual acuity compared with those who received fewer injections. This negative association is counterintuitive. However, because it is not possible to account for potential confounding factors such as disease severity in our analysis, further studies are needed to assess the optimal number of injections in standard clinical practice for different patients' groups. Only approximately 20% and 40% of the patients required vision rehabilitation after 1 year and 2 years, respectively, which is a great progress in the treatment of nAMD. Our findings thus provide valuable information for communicating with patients and for planning purposes in the health care system.
